Current Funding Opportunities

Click here to visit the NCI grant site.

Use your device's search function to find a specific disease or funding source. 

Tobacco Regulatory Science (R01 Clinical Trial Optional)

The purpose of this Funding Opportunity Announcement (FOA) is to invite R01 applications to support biomedical and behavioral research that will provide scientific data to inform regulation of tobacco products to protect public health.

Estimated Application Due Date: July 19, 2019

NCCN/AstraZeneca Quality of Care Evaluations in Advanced Ovarian Cancer

National Comprehensive Cancer Network® (NCCN®) is pleased to announce that it is collaborating with AstraZeneca Pharmaceuticals (AstraZeneca) to offer a new funding opportunity for improving patient care and outcomes in Stage III, Stage IV and recurrent epithelial ovarian cancer (EOC). The intent of this RFP is to encourage investigators at NCCN Member Institutions to submit letters of intent (LOIs) describing concepts for developing, implementing, and evaluating initiatives to improve patient outcomes in Stages III/IV and recurrent EOC. Studies aimed at enhancing the quality of multiple aspects of patient interaction and management throughout the clinical care continuum will be eligible. Special consideration will be given to “outside the box” innovative projects, with a special focus on optimizing testing and effectiveness of new healthcare-related paradigms.

Application Deadline: July 22, 2019, by 11:59 PM EST

Provocative Questions (PQs) in Cancer with an Underlying HIV Infection (R01 Clinical Trial Optional)

The purpose of this FOA is to continue advancing our understanding of the risks, development, progression, diagnosis, and treatment of malignancies observed in individuals with an underlying HIV infection or AIDS.

Application Deadline: August 1, 2019

Enhancing Academic-Community-Patient Partnerships in Metastatic Breast Cancer Care 

National Comprehensive Cancer Network® (NCCN®) is pleased to announce that it is collaborating with Pfizer Global Medical Grants (Pfizer) to offer a new grant opportunity for improving care for patients with metastatic breast cancer (MBC). The intent of this RFP is to encourage investigators at NCCN Member Institutions to submit proposals describing concepts for developing best practices and collaborative oncology care models between academic centers and referring community providers. The overarching goal is to leverage the expertise and resources of NCCN-designated cancer centers to improve quality and outcomes across the continuum of care for all MBC patients.

Proposal Deadline: 11:59 PM ET, August 28, 2019

Lasker Clinical Research Scholars Program (Si2/R00 Clinical Trial Optional)

This FOA encourages applications for the Lasker Clinical Research Scholars Program for the purpose of supporting the research activities during the early stage careers of independent clinical researchers. The program offers the opportunity for a unique bridge between the NIH intramural and extramural research communities and contains two phases. In the first phase, Lasker scholars will receive appointments for up to 5-7 years as tenure-track investigators within the NIH Intramural Research Program with independent research budgets. In the second phase, successful scholars will receive up to 3 years of NIH support for their research at an extramural research facility; or, the scholar can be considered to remain as an investigator within the intramural program.

Application Deadline: August 30, 2019, by 5:00 PM

Learn More>>

Susan G. Komen Career Catalyst Research Grant 

The topic area for the FY20 Career Catalyst Research Award is Redefining Metastatic Breast Cancer through Liquid Biopsy. The goal of this focus area is to support outstanding research seeking to use liquid biopsy techniques to improve treatment, detection, and understanding of metastatic breast cancer which will lead to a reduction in breast cancer deaths by 2026. Komen requests Letters of Intent for research projects that address one of the following focus areas: 
  • Refining treatment of metastatic breast cancer 
  • Early detection of metastatic breast cancer 
Applications that fit the focus areas as detailed in the LOI Announcement and include studies that address metastatic breast cancer disparities, or leverage data science to better understand and treat metastatic breast cancer are highly encouraged. The award provides funding up to $450,000 (direct and indirect costs combined) over 3 years. 

Application Deadline: September 25, 2019 

To Apply>> 
Learn More>> 

Defense Health Program  - Department of Defense Melanoma Research Program Funding Opportunities for Fiscal Year 2019 (FY19)

The FY19 Defense Appropriation provides $10 million (M) to the Department of Defense (DoD) Melanoma Research Program (MRP) to support innovative, high-impact melanoma research. 
FY19 MRP Program Announcements and General Application Instructions for the following award mechanism is posted on the website.

The FY19 MRP Focus Areas are listed below:
Precursor Lesions, Melanomagenesis, Host Factors, and the Tumor Microenvironment (e.g., melanoma instigators, ultraviolet [UV] exposure, other instigators)
Melanoma Primary Tumor Evolution (e.g., dormancy, heterogeneity, metabolism, epigenetic dysregulation, cell death)
Therapeutic Prevention
Minimal Residual Disease
Rare Melanomas (e.g., uveal, acral, leptomeningeal disease, pediatric, adolescent and young adult [AYA], mucosal)

The MRP challenges the research community to redefine the concept of prevention and has issued a FY19 MRP Challenge Statement that should be considered when responding to the FY19 MRP Focus Areas and funding opportunities. 

Concept Award
Investigators at or above postdoctoral fellow (or equivalent)
• Supports the exploration of highly innovative, untested, potentially groundbreaking concepts in melanoma.
• Emphasis is on Innovation.
• Preliminary data is strongly discouraged.
• Clinical trials are not allowed.
• Blinded review.
• The maximum allowable funding for the entire period of performance is $75,000 in direct costs.
• Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.
• The maximum period of performance is 1 year.

LOI Deadline: October 2, 2019; Application Deadline: October 23, 2019

Learn More>>

The Yale Cancer Center Internal Grant Program aims to provide funds for innovative, high quality start-up cancer research programs and provide new investigators with experience and guidance in the grant-writing process. 

The criteria for funding is high quality, innovative cancer research with a likelihood to result in NIH-funded cancer research and encourage collaborations within YCC. Grant competitions will be announced in DirectConnect and will undergo an anonymous NIH-style peer review with written reviews provided to applicants. 

Current opportunities are listed below. 

View a full list of grant opportunities available throughout the year>> 

Gabrielle's Angel Foundation for Cancer Research

The Foundation funds cutting-edge research in the fields of leukemia, lymphoma, and related cancers of the blood. Funds support promising scientists who are applying novel and state-of-the-art techniques to address fundamental problems in their genesis and treatment. Of interest are innovative clinical and basic science research that will lead to novel therapeutic approaches that could replace, or be used in combination with existing effective therapies. Focus is on projects for cancer prevention, detection and treatment that are most likely to be translated into clinical trials within a 3-5 year period.

Application Deadline: July 16, 2019

Luminary Award of Excellence

The YNHH Smilow Luminary Award of Excellence will serve to recognize, and ceremoniously acknowledge, those individuals and/or teams who consistently exceed performance expectations and deliver high quality cancer care for our patients, families and the health system through community service, optimization/ innovative solutions, patient experience, leadership and research initiatives. Nominations should be submitted directly to